CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 Provided by GlobeNewswire Jun 23 ...

Requiring Medicaid to cover obesity treatment would reduce long-term medical costs and address other diseases.

First Patient Enrolled in Acclarent AERA® Pediatric Registry ...

The company said its U.S. arm, Time-Cap Laboratories, received a compliance report from the U.S. drug regulator for its New ...

Tens of thousands of people suffer needless heart attacks and strokes every year because they aren't taking ...

Sufficient data from a 12-week non-clinical toxicology study of VYN202 in dogs would be required in order to resume the trial in male clinical subjects, and the design of this toxicology study has ...

The cellular action that enables the mouth's interior lining to heal quicky and without scarring has always been a mystery, ...

On Tuesday, the Santa Barbara County Grand Jury released the results of its investigation of three in-custody deaths at ...

This case is unique because it documents a rare occurrence of a Type IV stent fracture following percutaneous coronary ...

University of Cambridge study shows how LLM GPT-4 can generate novel combinations of drugs not typically used to treat cancer to be repurposed as potential breast cancer treatment in the future.

Mitochondria are not just the powerhouses of the cell – they are the immune system’s watchtowers, alert to even the faintest metabolic signals of bacterial invaders. As researchers’ understanding of ...